In Practise Logo
In Practise Logo - Blue
In Practise Logo
IP Interview
Published December 4, 2024

Veralto: Videojet Pharma Coding Solutions

Executive Bio

Former Pharma director at Videojet

Interview Transcript

Disclaimer: This interview is for informational purposes only and should not be relied upon as a basis for investment decisions. In Practise is an independent publisher and all opinions expressed by guests are solely their own opinions and do not reflect the opinion of In Practise.

This is a snippet of the transcript.to get full access.

And you mean each person on the manufacturing line, correct?

Yes, exactly. Not only the operators responsible for the printer, but also each time you have to change something in the printer's parameters, or if you want to change a cartridge or ink, you have to record everything. This is a requirement from the pharma market specifically for US. However, now it's global. You have specific software, and when you install any kind of printer, you must provide specific documentation.

This is a snippet of the transcript.to get full access.

So you mean the OEMs are the companies that sell the actual assembly line?

Yes, that's correct. It was about 50/50 because when I left, Videojet serialization was still at its peak, which is not the case anymore. There are fewer serialization projects now. I suppose the split is probably 70% on the end user and a maximum of 30% on the OEMs for pharma.

This is a snippet of the transcript.to get full access.

What's the typical cost of the equipment a customer would pay for? Let's think about one assembly line.

The printing cost is minimal compared to the cost of an assembly line. For a complete assembly line, we're talking about millions. How much? Around 2 or 2.5 million. The printers cost a maximum of €5,000 each.

This is a snippet of the transcript.to get full access.

Free Sample of 50+ Interviews

Sign up to test our content quality with a free sample of 50+ interviews.

Or contact sales for full access

© 2024 In Practise. All rights reserved. This material is for informational purposes only and should not be considered as investment advice.